/

Business

NEW MindMed MDMA trials, Compass Pathways Patent, Small Pharma DMT Trials Begins | MNMD, CMPS, DMT

NEW MindMed MDMA trials, Compass Pathways Patent, Small Pharma DMT Trials Begins | MNMD, CMPS, DMT What's up psychedelic investors! We have been seeing a lot of red in the last few months. Companies like MindMed (MNMD: NASDAQ) (MMED:NEO), Compass Pathways (CMPS: NASDAQ) &Small Pharma ( OTC: DMTTF) ( CVE: DMT) have had huge news in the last week. So in this episode we'll be covering the major news surrounding these psychedelic stocks! Enjoy the episode! Follow us on social media! 🙌 Instagram: @thepsychedelicinvestor Facebook: @thepsychedelicinvestor Want to collaborate? Send us an email at: thepsychedelicinvestor@gmail.com Music from: www.bensound.com Video editing: @themyaholy DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #CompassPathways #PsychedelicStocks

Psychedelic Business Spotlight: October 29

,
This week in psychedelic business news: MindMed's MDMA research pipeline to treat Autism Spectrum Disorder; Cybin EMBARKs; Awakn and MindCure partner to heal alcoholism.
Psychedelic Business Spotlight: October 22

Psychedelic Business Spotlight: October 22

,
This week in psychedelic business news: UK fast tracks DMT for major depressive disorder; Field Trip Health expands its clinical presence in the US; and another psychedelic pharmaceuticals company prepares for the Nasdaq.

A NEW Psilocybin-Depression Study Was Just Released: The Results Are BREATHTAKING | GAME OVER?🚀🍄

A NEW Psilocybin-Depression Study Was Just Released: The Results Are BREATHTAKING | GAME OVER?🚀🍄 Hello Psychedelic Investors! It’s an early Christmas today, as the results of a psilocybin to treat depression study were released. And the results are fantastic. This study, which used Comp 360, Compass Pathways’ (NASDAQ: CMPS) proprietary formulation of psilocybin (the active ingredient magic mushrooms) to treat Major Depressive Disorder, had fantastic results. 50% of people improved so much that they entered remission, and another 30% improved by more than 50%. For any followers of Psychedelic Stocks, this is amazing news, and it bodes well for Compass Pathways’ phase 2b psilocybin to treat treatment-resistant depression trials. As a reminder, this trial will be the most important event for psychedelic investors, as it is the largest ever psychedelic clinical trial. It is also the furthest advanced psilocybin clinical trial, being in phase 2b. Even if you don’t like Compass Pathways, this is very exciting news. This will benefit the entire psychedelics industry, including companies like MindMed (MNMD), Red Light Holland (TRIP), atai Life Sciences (atai) and more. Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! Instagram: @psychedelicinvestor James Twitter: @PSY_Invest Maria’s Twitter: @PSY_Holy Facebook: @thepsychedelicinvestor Email: thepsychedelicinvestor@gmail.com Music: www.bensound.com Reference: https://psilocybinalpha.com/news/open-label-study-of-comp360-psilocybin-therapy-for-depression-in-cancer-patients-demonstrates-feasibility-of-simultaneous-psilocybin-administration-in-small-groups DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #CompassPathways #Psilocybin #Psychedelics

How to Microdose Magic Mushrooms in 5 EASY Steps For Beginners (Plus: Does Microdosing Really Work?)

In this episode, we're covering what is microdosing and its purported benefits. You will learn how to microdose magic mushrooms. How to microdose psychedelics. Microdosing is the practice of taking a small dose of a drug, in our case psilocybin, the main active ingredient in magic mushrooms. The dose is small enough that it won’t cause any perceptual changes, meaning you won’t have any hallucinations or even feel high. This will allow you to continue to go to school, work, or get more comfortable in social settings. According to thousands upon thousands of anecdotal stories over decades, microdosing psilocybin is purported to: - Improve your creativity; - Help you enter states of flow, also known as “being in the zone” or entering a mental state of total energized concentration; - Help alleviate feelings of stress and anxiety; - Improve focus and concentration; - Improves relational awareness and; - Speeds your reflexes. We have to rely on anecdotal evidence unfortunately, because until recently, very little scientific study has been done on the subject of microdosing, though that is starting to change with many clinical studies underway. Despite a lack of hard scientific data, the practice is sworn upon by many in high pace environments, such as Silicon Valley. A couple famous examples of microdosers include: Joe Rogan and Steve Jobs, though for the later it was more LSD microdosing. Let me know in the comments if you want to see a video on LSD microdosing in the future. Enjoy the episode! Follow us on social media! 🙌 Instagram: @thepsychedelicinvestor Facebook: @thepsychedelicinvestor Want to collaborate? Send us an email at: thepsychedelicinvestor@gmail.com Music from: www.bensound.com Video editing: @themyaholy Check out our Benziga discounts https://benzinga.grsm.io/jameshallifa... https://benzinga.grsm.io/thepsychedel... DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MicrodosingMushrooms #Microdosing #MagicMushrooms

Interview with Patrick Moher, CEO of Microdose

,
In this chat, he discusses some of the challenges involved in moving virtual events to an in-person conference (during a pandemic), who and what to expect at the event, and why Wonderland Miami is not just any other conference, but a one-of-a-kind experience. 

The PROBLEM With Psilocybin – How Is BRIGHT MINDS Fixing That? (DRUG/BMBIF)

The PROBLEM With Psilocybin - How Is BRIGHT MINDS Fixing That? (DRUG/BMBIF) In the interview we discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain. I had a blast in this interview, and I know you will find it fascinating! Enjoy! DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. Follow us on social media! 🙌 Instagram: @thepsychedelicinvestor Facebook: @thepsychedelicinvestor Want to collaborate? Send us an email at: thepsychedelicinvestor@gmail.com Music from: www.bensound.com Video editing: @themyaholy Check out our Benziga discounts https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor Full Disclosure: This video is for entertainment only and shouldn't be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. The Psychedelic Investor has been hired for a period beginning on 28,09,2021 and ending on 29,09,2021 to publicly disseminate information about (BRIGHT MINDS BIOSCIENCE INC) via digital communications. We have been paid ($2000 CAD). #BrightMinds #PsychedelicStocks #Psilocybin

Psychedelic Business Spotlight: October 15

,
This week in psychedelic business news: Cybin inhales; atai Life Sciences expands; DEA grants new psilocybin license; and FDA backs ketamine.

Why Are Psychedelic Stocks Falling? (MindMed, Atai, Cybin, FieldTrip, Compass Pathways)

What's up psychedelic investors! We have been seeing a lot of red in the last few months. Companies like MindMed (MNMD: NASDAQ) (MMED:NEO), atai Life Sciences (atai: NASDAQ), Field Trip (FTRP: TSE) ( FTRP: NASDAQ), Cybin (CYBN: NYSE) and many more have experienced a decline in stock prices. So in this episode, we'll be discussing the reasons behind this and whether we are ignoring some red flags. Enjoy the episode! Follow us on social media! 🙌 Instagram: @thepsychedelicinvestor Facebook: @thepsychedelicinvestor Want to collaborate? Send us an email at: thepsychedelicinvestor@gmail.com Music from: www.bensound.com Video editing: @themyaholy Check out our Benziga discounts https://benzinga.grsm.io/jameshallifa... https://benzinga.grsm.io/thepsychedel... DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #FieldTrip #PsychedelicStocks

© 2023 Psychedelic Spotlight. | Owned and operated by PSYC Media Corporation, Inc. a US publicly traded company (OTCPink: PSYC) | All Rights Reserved.